[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR860000863A - 스테로이드 에스테르류를 함유하는 리포솜의 제조방법 - Google Patents

스테로이드 에스테르류를 함유하는 리포솜의 제조방법 Download PDF

Info

Publication number
KR860000863A
KR860000863A KR1019850005440A KR850005440A KR860000863A KR 860000863 A KR860000863 A KR 860000863A KR 1019850005440 A KR1019850005440 A KR 1019850005440A KR 850005440 A KR850005440 A KR 850005440A KR 860000863 A KR860000863 A KR 860000863A
Authority
KR
South Korea
Prior art keywords
compound
general formula
defined above
formula
following general
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019850005440A
Other languages
English (en)
Other versions
KR930000045B1 (ko
Inventor
벵트 잉게마르 악셀손 (외 4)
Original Assignee
칼 거스타프 요한슨
악티에볼라게트 드라코
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칼 거스타프 요한슨, 악티에볼라게트 드라코 filed Critical 칼 거스타프 요한슨
Publication of KR860000863A publication Critical patent/KR860000863A/ko
Application granted granted Critical
Publication of KR930000045B1 publication Critical patent/KR930000045B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

스테로이드 에스테르류를 함유하는 리포솜의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 리포솜과 하기 일반식(Ⅰ)의 화합물을 결합해서 된 주로 호흡기관투여용 약제.
    상기 식중, Q는 다음과 같고,
    R1는 11-19개의 탄소 원자를 갖는 포화 또는 불포화, 직쇄 또는 측쇄알킬기이고, [R는 -COCH3, -COC2H5, -CO(CH2)2CH3또는 -CO(CH2)3CH3이다].
  2. 제1항에 있어서, 일반식(Ⅰ)의 화합물이 제20위치 탄소원자의 치환체 배열에 관하여 R또는 S형의 입체이성질체혼합물, 또는 에피머 형태인 조성물.
  3. 제1항에 있어서, 일반식(Ⅰ)의 화합물을 함유하는 동결건조된 리포솜제로 된 조성물.
  4. a) 일반식(Ⅰ)(제1항에서 정의한 바와 같음)의 화합물과 레시틴을 유기 용매 중에서 용해시키고,
    b) 용매를 증발시키고, 그리하여 리포솜을 수용성 매질 중에서 직접적으로 얻거나, 또는
    c) 용매를 증발시킨 후에, 리피드 층을 수용성 매질(락토오스를 함유하거나 또는 함유하지 않음)중에 분산시키고,
    d) 생성된 현탁액을 흔들어주거나 또는 초음파 진동시키거나, 또는 다른 방법으로,
    e) 리포솜 현탁액을 건조시킴을 특징으로 하는 제1항에 의한 약제의 제조 방법.
  5. 하기 일반식(Ⅰ)의 화합물.
    [상기 식중, Q 는 다음과 같고,
    R1는 11-19개의 탄소 원자를 갖는 포화 또는 불포화, 직쇄 또는 측쇄알킬기이고, R는 H, -COCH3, -COC2H5, -CO(CH2)2CH3또는 -CO(CH2)3CH이다]
  6. 제5항에 있어서, 일반식(Ⅰ)의 화합물이 제20위치 탄소원자의 치환체 배열에 관하여 R 또는 S형의 입체이성질체 화합물 또는 에퍼머의 형태인 조성물.
  7. a) 하기 일반식의 화합물을
    Q-QH
    (식중, Q는 상기 정의한 바와 같음)
    다음 일반식의 화합물과 반응시켜서 일반식(Ⅰ)의 화합물을 얻거나, 또는
    R1-COOH
    (식중, R1는 상기 정의한 바와 같음)
    b) 하기 일반식의 화합물을
    Q-OH
    (식중, Q는 상기 정의한 바와 같음)
    다음 일반식의 화합물과 반응시켜서 일반식(Ⅰ)의 화합물을 얻거나, 또는
    R1CO-X
    [식중, R1는 상기 정의한 바와 같고, X는 할로겐 원자 또는(여기에서, R2는 R1에서 정의한 바와 같음)기임], 또는 c)하기 일반식의 화합물을
    Q-X1
    (식중, Q는 상기 정의한 바와 같고, X1는 이탈기임)
    다음 일반식의 화합물
    (식중, R1는 상기 정의한 바와 같고, A 는 양이온임)과 반응시킴을 특징으로 하는 하기 일반식(Ⅰ)의 화합물의 제조방법.
    (식중, Q는 R1는 제5항에서 정의한 바와 같음)
  8. 제7항에 있어서, 제6항에 의한 화합물을 제조하는 것을 특징으로 하는 방법.
  9. 제1항의 약제를 치료가 요구되는 숙주에 유효량으로 투여시킴을 특징으로 하는 인체를 비롯한 포유료 동물에 있어서 염증을 치료 및 억제시키는 방법.
  10. 약품으로서 사용하기 위한 제5-제6항 중 어느 항에 의한 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850005440A 1984-07-30 1985-07-29 스테로이드 에스테르류를 함유하는 리포솜의 제조 방법 Expired - Fee Related KR930000045B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8403905A SE8403905D0 (sv) 1984-07-30 1984-07-30 Liposomes and steroid esters
SE8403905-6 1984-07-30

Publications (2)

Publication Number Publication Date
KR860000863A true KR860000863A (ko) 1986-02-20
KR930000045B1 KR930000045B1 (ko) 1993-01-06

Family

ID=20356623

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850005440A Expired - Fee Related KR930000045B1 (ko) 1984-07-30 1985-07-29 스테로이드 에스테르류를 함유하는 리포솜의 제조 방법

Country Status (29)

Country Link
US (1) US4693999A (ko)
EP (1) EP0170642B1 (ko)
JP (1) JPS6143110A (ko)
KR (1) KR930000045B1 (ko)
AT (1) ATE60990T1 (ko)
AU (1) AU582173B2 (ko)
CA (1) CA1250830A (ko)
CS (1) CS254342B2 (ko)
CY (1) CY1731A (ko)
DD (2) DD248055A5 (ko)
DE (1) DE3581856D1 (ko)
DK (1) DK164509C (ko)
EG (1) EG17462A (ko)
ES (2) ES8704969A1 (ko)
FI (1) FI84914C (ko)
HK (1) HK78293A (ko)
HU (1) HU196827B (ko)
IE (1) IE58074B1 (ko)
IS (1) IS1515B (ko)
NO (1) NO168042C (ko)
NZ (1) NZ212861A (ko)
PH (1) PH21644A (ko)
PL (1) PL145673B1 (ko)
PT (1) PT80884B (ko)
SE (1) SE8403905D0 (ko)
SG (1) SG69093G (ko)
SU (1) SU1493111A3 (ko)
YU (1) YU45735B (ko)
ZA (1) ZA855032B (ko)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
SE8501693D0 (sv) * 1985-04-04 1985-04-04 Draco Ab Novel 16,17-acetalsubstituted androstane-17beta-carboxylic acid esters
SE8506015D0 (sv) * 1985-12-19 1985-12-19 Draco Ab Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives
SE8601457D0 (sv) * 1986-04-01 1986-04-01 Draco Ab Compositions of liposomes and b?712-receptor active substances for inhalation
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
FR2619505B1 (fr) * 1987-08-20 1990-08-31 Dior Christian Parfums Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant de la pregnenolone ou un ester de pregnenolone, et composition cosmetique ou pharmaceutique, notamment dermatologique, a activite regeneratrice ou revitalisante, l'incorporant
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
EP0397774A1 (en) * 1988-02-04 1990-11-22 Board Of Regents, The University Of Texas System Formulation and use of retinoids in treatment of cancer and other diseases
WO1990006775A1 (en) * 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
US5043165A (en) * 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US6146657A (en) * 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5776429A (en) * 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US6001335A (en) * 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US20020150539A1 (en) 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5888995A (en) * 1991-02-04 1999-03-30 Astra Aktiebolag Steroid esters
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5874062A (en) * 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
FR2675146A1 (fr) * 1991-04-10 1992-10-16 Roussel Uclaf Nouveaux derives sterouides de la pregna-1,4-diene-3,20-dione, leur preparation, leur application a la preparation de derives 16,17-methylene dioxy substitues et nouveaux intermediaires.
FI953358L (fi) * 1993-01-08 1995-07-07 Astra Ab Uudet paksusuolelle- ja sykkyräsuolelle spesifiset steroidijohdannaiset
WO1994028876A1 (en) * 1993-06-07 1994-12-22 Advanced Therapies, Inc. Liposome powders
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5635206A (en) * 1994-01-20 1997-06-03 Hoffmann-La Roche Inc. Process for liposomes or proliposomes
CH689139A5 (de) * 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5997898A (en) * 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
AU736301B2 (en) 1996-05-01 2001-07-26 Imarx Therapeutics, Inc. Methods for delivering compounds into a cell
US5958378A (en) * 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
TW497974B (en) * 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
AU736056B2 (en) * 1996-09-11 2001-07-26 Imarx Pharmaceutical Corp. Improved methods for diagnostic imaging using a contrast agent and a vasodilator
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
AU6974798A (en) * 1997-05-06 1998-11-27 Imarx Pharmaceutical Corp. Novel prodrugs comprising fluorinated amphiphiles
US7452551B1 (en) 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
WO2001023405A2 (en) 1999-09-30 2001-04-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
JP2003520210A (ja) * 2000-01-05 2003-07-02 イマレックス セラピューティクス， インコーポレイテッド 低い水溶性を有する薬物の送達のための薬学的処方物
DE10116197A1 (de) * 2001-03-30 2002-10-17 Bernina Biosystems Gmbh Neue Methylprednisolonderivate mit therapeutischer Wirkung
AU2003217535A1 (en) 2002-02-20 2003-09-09 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids
US20050009798A1 (en) 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
AU2003230600B2 (en) * 2002-03-05 2009-06-04 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
AU2003291634A1 (en) * 2002-10-08 2004-05-04 Sepracor Inc. Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
KR101504616B1 (ko) * 2002-10-29 2015-03-23 인스메드 인코포레이티드 항감염제의 지속적인 방출
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
AU2003257154A1 (en) * 2003-08-05 2005-03-07 Sepracor Inc. AMINO ACID AND PEPTIDE-MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH ss2 ADRENERGIC AGONISTS
EP3067046B1 (en) 2005-12-08 2020-03-25 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
NO331891B1 (no) * 2007-03-20 2012-04-30 Clavis Pharma Asa Kjemiske forbindelser, et farmasoytisk preparat inneholdende slike forbindelser, samt anvendelse derav for behandling av kreft, inflammasjon og KOLS
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
KR102277921B1 (ko) 2012-05-21 2021-07-14 인스메드 인코포레이티드 폐 감염을 치료하기 위한 시스템
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
KR20240018675A (ko) 2014-05-15 2024-02-13 인스메드 인코포레이티드 폐의 비-결핵성 마이코박테리아 감염을 치료하기 위한 방법
KR101961484B1 (ko) * 2016-01-08 2019-03-22 최규선 생콩 탈피장치
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE378109B (ko) * 1972-05-19 1975-08-18 Bofors Ab
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
CH621479A5 (ko) * 1977-08-05 1981-02-13 Battelle Memorial Institute
FR2416008A1 (fr) * 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
JPS609726B2 (ja) * 1980-05-15 1985-03-12 株式会社 ミドリ十字 ステロイド製剤
HU182775B (en) * 1981-10-15 1984-03-28 Richter Gedeon Vegyeszet Process for preparing new 3-chloro-pregnane derivatives
DE3228629A1 (de) * 1982-07-31 1984-02-02 Reifenrath, Rainer Richard Otto, Dr., 3104 Unterlüß Pharmazeutisches erzeugnis zur behandlung der atemwege und verfahren zu seiner herstellung
GB2135647A (en) * 1983-02-15 1984-09-05 Squibb & Sons Inc Method of preparing liposomes and products produced thereby

Also Published As

Publication number Publication date
FI852932L (fi) 1986-01-31
AU582173B2 (en) 1989-03-16
NO852672L (no) 1986-01-31
PL145673B1 (en) 1988-10-31
ES557143A0 (es) 1987-05-16
IS3026A7 (is) 1986-01-31
HK78293A (en) 1993-08-13
FI852932A0 (fi) 1985-07-29
KR930000045B1 (ko) 1993-01-06
IS1515B (is) 1992-11-04
YU123885A (en) 1988-02-29
PT80884B (pt) 1987-11-30
IE851892L (en) 1986-01-30
SU1493111A3 (ru) 1989-07-07
FI84914B (fi) 1991-10-31
SG69093G (en) 1993-08-06
SE8403905D0 (sv) 1984-07-30
NO168042B (no) 1991-09-30
DK336385D0 (da) 1985-07-24
JPH0459297B2 (ko) 1992-09-21
EP0170642A3 (en) 1986-10-29
JPS6143110A (ja) 1986-03-01
EP0170642A2 (en) 1986-02-05
CS254342B2 (en) 1988-01-15
DD236535A5 (de) 1986-06-11
CY1731A (en) 1994-05-06
ES8704969A1 (es) 1987-04-16
DK164509B (da) 1992-07-06
ZA855032B (en) 1986-03-26
DK164509C (da) 1992-11-23
PT80884A (en) 1985-08-01
ES545651A0 (es) 1987-04-16
DE3581856D1 (de) 1991-04-04
PH21644A (en) 1988-01-13
DK336385A (da) 1986-01-31
HUT39460A (en) 1986-09-29
HU196827B (en) 1989-01-30
CA1250830A (en) 1989-03-07
US4693999A (en) 1987-09-15
PL254681A1 (en) 1986-11-18
EG17462A (en) 1991-03-30
NZ212861A (en) 1989-01-27
NO168042C (no) 1992-01-08
EP0170642B1 (en) 1991-02-27
IE58074B1 (en) 1993-06-30
DD248055A5 (de) 1987-07-29
ES8705895A1 (es) 1987-05-16
YU45735B (sh) 1992-07-20
AU4530785A (en) 1986-02-06
ATE60990T1 (de) 1991-03-15
FI84914C (fi) 1992-02-10

Similar Documents

Publication Publication Date Title
KR860000863A (ko) 스테로이드 에스테르류를 함유하는 리포솜의 제조방법
KR890006603A (ko) 항균제로 유용한 아미노메틸 옥소옥사졸리디닐 에테닐벤젠 유도체
KR900011772A (ko) 3-(1,2,5,6-테트라하이드로피리딜)피롤로피리딘
KR880003939A (ko) 피페리딘 화합물과 이의 제조방법 및 용도
KR890016036A (ko) 아스코르브산 2-포스페이트 에스테르
KR940701264A (ko) 안과질환에 대한 마크로라이드 화합물의 용도
DK160129C (da) Farmaceutisk praeparat indeholdende en gangliosidforbindelse, et indre ester-gangliosidderivat eller blandinger deraf
KR900005978A (ko) 키니딘, 아르테미시닌 및 이의 유도체를 사용한 항말라리아 조성물 및 치료방법
KR890003691A (ko) 피페리딘 유도체 및 그를 함유하는 부정맥을 위한 치료예방제
KR900016203A (ko) 신규 화합물들
KR890014480A (ko) 2-피리딜아세트산 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR900016135A (ko) 피부 및 점막-상피의 질환 치료용 4-퀴놀린 카복실산 유도체
KR890000395A (ko) 페놀, 유도체, 그의 제조방법 및 용도
FR2623808B1 (fr) Nouveaux derives flavonoides (benzyl-4 piperazinyl-1)-2 oxo-2 ethylene substitues, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
KR890003752A (ko) 2-피리미디닐-피페라딘 유도체의 용도
KR900001715A (ko) Bu-3608 유도체
US3600427A (en) Phenyl carbamate latentiated phenethylamines
KR900700098A (ko) 발기부전의 치료겸 진단용 플라복세이트 및 그 유도체
KR910018348A (ko) 술포닐아미노치환 비시클로환계 히드록삼산 유도체
KR900012881A (ko) 2,3,23-트리하이드록시-우르스-12-엔 및 이의 유도체 이의 제조방법 및 이의 용도
KR900004697A (ko) 고콜레스테롤 혈증치료용 4,5-디아릴-2- 치환된 티오이미다졸
KR880002519A (ko) 신경변질 치료용 안 조성물
KR890009901A (ko) 3-히드록시-2-(4-메톡시페닐)-5-(2-메틸아미노에틸)-2,3-디히드로-5h-1,5- 벤조티아제핀-4-온 유도체, 그의 제조 및 치료에의 이용
KR880001596A (ko) 디하이드로피리딘 화합물-함유 뇌기능이상 치료제
KR970064604A (ko) 벤조피란 유도체 및 그의 심장질환 치료제로서의 용도

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19850729

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19900728

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19850729

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19920811

Patent event code: PE09021S01D

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19921130

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19930327

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19930624

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19930624

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 19960104

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 19961220

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 19961220

Start annual number: 5

End annual number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee